From Malabsorption to Management: Treatment and Therapy

Managing PCSK1 deficiency is a process of constant adaptation. Because your child’s needs change so dramatically between infancy and early childhood, their management plan must shift from survival and growth to the complex task of regulating a hunger that their brain cannot turn off on its own.

The First Priority: Surviving the Diarrhea Phase

In the first weeks and months of life, the primary goal is ensuring your child receives enough nutrients to survive and grow. Because their intestines cannot properly absorb fats and sugars, standard feeding often fails ^[1].

For many infants with this condition, parenteral nutrition (PN)—nutrition delivered directly into the bloodstream through a vein—may be necessary ^[2][3]. In some cases, this is a necessary way to support normal brain and body development during the first year of life ^[2]. However, PN carries serious risks, including central-line infection, thrombosis, and liver disease. This phase requires a specialized team, including a pediatric gastroenterologist and a dietitian experienced in intestinal failure, to monitor electrolytes and prevent complications like dehydration ^[4][5].

The Role of Diet, Exercise, and Targeted Therapy

As the diarrhea phase stabilizes, parents often encounter a new, equally overwhelming challenge: hyperphagia, or an intense, biologically driven hunger ^[6].

It is vital for parents to understand that this hunger and the resulting weight gain are not the result of poor parenting or a lack of willpower. Because the “scissors” (the PC1/3 enzyme) are missing, the brain never receives the hormonal signal that the stomach is full ^[7].

• Traditional Diets Fail: In genetic obesity like PCSK1 deficiency, the body’s metabolic “thermostat” is broken. While structured lifestyle interventions—such as working with a dietitian to create a balanced meal plan, ensuring safe food environments, and encouraging physical activity—are essential components of comprehensive care, standard calorie-restricted diets alone often fail to override this powerful genetic drive ^[8].
• A “Pathway” Disease: This is a biological signaling error. Telling a child with this condition to “just eat less” is like telling a person with a broken leg to “just walk faster.”

Setmelanotide: Restoring the “Fullness” Signal

In recent years, a targeted treatment called setmelanotide (Imcivree) has changed the management of PCSK1 deficiency.

Setmelanotide is an MC4R agonist. It works by bypassing the broken hormone “scissors” and directly activating the melanocortin-4 receptor in the brain—the specific switch that tells the body it is full and should burn energy ^[9][10].

• Eligibility and Dosing: Regulatory approvals and age minimums vary by country and date. Your prescribing specialist must determine eligibility based on confirmed biallelic PCSK1 deficiency and establish an individualized dosing and titration schedule based on current product labeling and your child’s age, weight, and tolerability ^[11].
• Scope of Treatment: Setmelanotide specifically targets hyperphagia and obesity; it does not replace the need for thyroid, adrenal, growth hormone, or water-balance treatments.

Managing Side Effects: “The Skin and the Sting”

While setmelanotide can significantly reduce hunger and stabilize weight, it does have common side effects that parents should prepare for:

1. Skin Darkening (Hyperpigmentation): Because the medication is similar to the hormone that controls skin color, about 62% of patients experience skin darkening or the appearance of new, darker moles (nevi) ^[12][9]. You should have a baseline dermatology exam before starting and annual checkups to monitor these changes ^[13][14]. Contact your doctor if you notice new or changing moles.
2. Psychiatric and Mood Changes: The product label warns of the potential for mood changes, depression, or suicidal thoughts. Caregivers should monitor closely for any sudden changes in mood or behavior and report them urgently.
3. Injection-Site Reactions and Nausea: This is a daily injection under the skin. Up to 96% of patients experience some redness, itching, or swelling at the injection site ^[12]. Nausea and vomiting can also occur, especially during the first few weeks ^[15][12].
4. Other Adverse Effects: The label also notes potential heart rate changes and, in some patients, sexual adverse effects (such as spontaneous erections).

By shifting the focus from “restricting food” to “restoring signals,” you can move away from the constant battle of hyperphagia and toward a management plan that works with your child’s unique biology.